PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

BioWin signs an agreement with Juke Biotech Park

BioWin signs an agreement with Juke Biotech Park, a major science park in Shanghai active in the field of health biotechnologies and medical technologies
Gosselies, November 2011 – BioWin, the Health competitiveness cluster of Wallonia (Belgium), has announced that a partnership agreement was signed on the 14th of October of this year with Juke Biotech Park, a new public funded Science Park in Shanghai (China) that hosts more than a hundred Chinese SMEs and research centres specialised in health biotechnologies and medical technologies. Under the agreement, an operational infrastructure and facilities will be provided to Laurent Le Guyader, BioWin’s permanent representative in Shanghai as International  Relations Manager – China. Mr Le Guyader reports to Yve van Thorenburg, International Relations Manager – Asia and Frédéric Druck, who heads the BioWin international unit. Juke Biotech Park has further undertaken to smooth the way for access to the Chinese market to BioWin members. And vice versa, BioWin will ease as much as possible the access of Juke Biotech Park companies to Wallonia as strategic gate to the European market. This agreement is the fruit of a strategy to develop the BioWin activities in China, first launched in 2009. It was signed in the course of a recent BioWin and AWEX (Walloon Export and Foreign Investment Agency) mission to the Bio China trade fair 2011. BioWin was eager to conclude this agreement to keep step with the growing interest for the Chinese market expressed by Walloon SMEs and research centres working in the field of health biotechnologies and medical technologies. This is the second agreement concluded with a preferred partner on location in Shanghai, the Chinese city that has become an indispensable hub when it comes to healthcare innovation.
***
Press contacts: Frédéric Druck – BioWin Head of Communication and International
Relations
Tel. +32 (0)474/52.02.69 – frederic.druck@biowin.org
BioWin – The Health Cluster of Wallonia
www.biowin.org

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026